Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

EAG Acquires PTRL West and PTRL Europe

Published: Thursday, April 12, 2012
Last Updated: Thursday, April 12, 2012
Bookmark and Share
EAG adds new division to serve high-end analytical testing needs of the chemical and pesticide industry.

Evans Analytical Group, Inc. (EAG) has announced that it has acquired PTRL West, Inc. (Hercules, CA) and PTRL Europe GmbH (Ulm, Germany).

PTRL West and PTRL Europe will continue to operate under their current names and locations as divisions of EAG. Financial terms of the transaction were not disclosed.

PTRL has created a world-wide business serving the regulatory testing needs of the leading international agrochemical companies.

PTRL provides specialized services in Analytical Chemistry and Residue Analysis, Environmental Fate and Metabolism to assist in the required regulatory testing to bring new pesticides to market and to perform testing required for re-registrations of compounds.

PTRL serves the regulatory requirements of the U.S. EPA, U.S. FDA, EU, REACH, OECD and JMAFF governmental agencies.

The work conducted at the PTRL facilities is in compliance with Good Laboratory Practices (GLP) for the Agrochemical industry and complements our GLP work for the pharmaceutical industry conducted within our EAG Life Sciences Division.

With a continuing commitment to scientific expertise, accuracy of chemical analysis, investment in advanced instrumentation and technologies, and building long-term business partnerships with customers, PTRL has established itself as the premier laboratory for executing challenging analytical work.

For over 20-years, customers from the U.S, Europe and Japan have relied on PTRL as a trusted partner in the complex, regulated process of bringing new pesticides to market.

Harry Davoody, CEO of EAG states "Both PTRL and EAG value our customer relationships first and foremost. The acquisition of PTRL was very compelling to EAG and fits into EAG's overall growth strategy in offering a broader range of high-end analytical services for new and existing customers of EAG. EAG's different divisional strengths complement each other with their best-in-class subject matter expertise which is highly valued by our specialized customers."

Dr. Luis Ruzo, co-founder and Head of PTRL West, affirmed that "PTRL is pleased to become part of an organization as well-regarded as EAG. This merger is very important to PTRL, providing us with additional resources from a solid long-standing company which supports our efforts to continue to grow our labs and our capabilities for our valued customers."

Dr. Thomas Class, co-founder and Head of PTRL Europe, noted "PTRL carefully selected EAG knowing that PTRL and its team will be part of EAG's future growth engine beyond EAG's existing markets. EAG recognized the potential in the agrochemical segment and is very committed to further investing in our business going forward."

Virginia M. Turezyn, SVP of Business Development and Strategy, comments "The agrochemical market sector has been on our radar for some time and we were pleased to have the best-in-class management and team at PTRL to serve as the cornerstone for EAG's entry into this industry."

Neal McCarthy, Managing Director of Fairmount Partners, who assisted PTRL and EAG in this transaction commented "With the acquisition of PTRL, EAG has added the finest agrochemical lab in North America and Europe, and with Dr. Luis Ruzo and Dr. Thomas Class and the other PTRL scientists, EAG adds world class experts in the field of agrochemicals, to its impressive roster of scientific talent."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos